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Sites of Colonization with Extended-
Spectrum jS-Lactamases (ESBL)-
Producing Enterobacteriaceae: 
The Rationale for Screening 
Extended-spectrum ^-lactamases (ESBL)-producing organ-
isms have emerged as one of the most important multi-
resistant pathogens in hospitals.1 They are spreading in the 
community worldwide, mainly causing urinary tract infec-
tions.2 Infections caused by ESBL-producing organisms are 
associated with poor outcomes, reduced rates of clinical re-
sponse, longer hospital stays, and greater expenses.3 Author-
ities at the Centers for Disease Control and Prevention (CDC) 
recommend performance of active surveillance cultures from 
patients in populations at risk, for example, patients in in-
tensive care, burn, bone marrow or stem cell transplant, and 
oncology units, patients transferred from facilities known to 
have high prevalence rates, roommates of colonized or in-
fected persons, and patients known to have been previously 
infected or colonized.4 Despite the CDC's recommendation, 
standardized screening schemes for carriage of multiresistant 
gram-negative pathogens, including ESBL-producing Enter-
obacteriaceae, are lacking. Knowledge of the body sites most 
commonly colonized with these pathogens is of great im-
portance to inform appropriate and cost-effective screening 
procedure policies. The aim of this study, therefore, was to 
determine the frequency of colonization for each body site. 
University Hospital Basel is an 855-bed tertiary care center 
with 5 intensive care units (ICUs). The study was approved 
by the local ethics committee as part of the quality assurance 
program. From January 2008 to December 2010, all consec-
utive adult patients in whom an ESBL-producing Entero-
bacteriaceae was detected in any clinical specimen routinely 
taken for suspected infection were included in the study. Pa-
tients were screened for colonization by examination of urine 
samples and rectal, inguinal, and throat swabs. Specimens 
were cultured onto the chromogenic BBL CHROMagar Ori-
entation medium (Becton Dickinson) or chromID ESBL me-
dium (bioMerieux). No screening was performed if patients 
were receiving antibiotics active against ESBL-producing En-
terobacteriaceae, as this may have led to false-negative screen-
ing results. Patients who did not receive screening of all 4 
body sites (urine, rectum, groin, and throat) were excluded. 
For microbiological detection of ESBL producers, the 
guidelines of the Clinical and Laboratory Standards Institute 
were followed.5 The frequency of detection was calculated for 
each site. The proportion of CTX-M genotype was deter-
mined by polymerase chain reaction using the degenerative 
oligonucleotides CTX-F2 (5'-GTGCAGYACCAGTAARGT-
KATGG-3') and CTX-M-R1 (5'-CDCMGCT GCCGGTYT-
TATC-3').6'7 Sequencing of amplicons was performed with an 
ABI 3130 Genetic Analyzer (Applied Biosystems). ESBL-
producing strains were detected in 204 patients, of whom 133 
(65.2%) had all 4 sites swabbed and 58 (28.4%) did not 
undergo swabbing because they were under treatment with 
a systemic antibiotic with activity against ESBL-producing 
pathogens or had already been discharged or transferred to 
another hospital. The remaining 13 patients (6.4%) were 
swabbed in 1 or 2 of the 4 sites but not in all 4 because of 
noncompliance with written instructions. Of the 133 patients 
swabbed at all 4 sites, 60 (45.1%) were hospitalized on the 
medical wards, 44 (33.1%) on the general surgical wards, 17 
(12.8%) on the gynecology department, 8 (6.0%) on the urol-
ogy department, 2 (1.5%) on the neurology department, and 
2 (1.5%) on the bone marrow transplant unit. Patients' me-
dian age was 66 years (range, 18-93), with a female predom-
inance of 60.2% (80/133 patients). 
Escherichia coli accounted for the majority of all ESBL-
producing Enterobacteriaceae (85.7%, 114/133), followed by 
Klebsiella pneumoniae (13.5%, 18/133) and Citrobacter freun-
dii (0.8%, 1/133). The CTX-M genotype was detected in 109 
of 133 patients (82.0%), accounting for 85.1% (97/114) of 
all ESBL-producing E. coli and 66.7% (12/18) of ESBL-
producing K. pneumoniae isolates. 
ESBL-producing Enterobacteriaceae were most commonly 
recovered from urine samples, which were positive in 82.7% 
(110/133) of patients, followed by rectal swabs (69.2%, 92/ 
133), skin swabs of the groin (35.3%, 47/133), and throat 
swabs (12.8%, 17/133; Table 1). 
Urine and the rectum were most commonly colonized with 
ESBL-producing Enterobacteriaceae (82.7% and 69.2%, re-
spectively). Our finding that urine was the only positive 
screening site in 24.1% of our patients provides strong evi-
dence that urine samples should be included in a standardized 
screening regimen. 
The CDC recommends performance of active surveillance 
cultures for patients from populations at risk,4 as patients 
colonized with ESBL-producing Enterobacteriaceae are at in-
creased risk to develop invasive infections with these path-
ogens. A 5-fold increased risk for invasive infection with an 
ESBL-producing Enterobacteriaceae for ICU patients with 
rectal colonization has been described,8 and Reddy et al9 
found that 8.5% of patients colonized with ESBL-producing 
Enterobacteriaceae developed subsequent bloodstream infec-
tions with these pathogens. The authors therefore concluded 
that active surveillance for ESBL-producing Enterobacteria-
ceae may have important clinical implications for empiric 
treatment of febrile episodes. In these 2 studies, however, 
screening for colonization was performed only by collection 
of rectal swabs. More than 20% of ESBL-positive patients 
may remain undetected with this approach, which does not 
include screening of the urine. 
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TABLE 1. Overview of the Different Colonization Patterns 
Detected in 133 Patients 
No. of 
Pattern \ patients (%) 
1 colonization site 
Urine 
Rectum 
Groin 
Throat 
2 colonization sites 
Urine, rectum 
Urine, groin 
Urine, throat 
Rectum, groin 
Rectum, throat 
Groin, throat 
3 colonization sites 
Urine, rectum, groin 
Urine, rectum, throat 
Urine, groin, throat 
Rectum, groin, throat 
4 colonization sites 
Urine, rectum, groin, throat 
Site totals 
Patients with colonization of the 
Patients with colonization of the 
Patients with colonization of the 
urine 
rectum 
groin 
Patients with colonization of the throat 
32 (24.1) 
11 (8.3) 
1 (0.7) 
1 (0.7) 
38 (28.6) 
5 (3.8) 
1 (0.7) 
6 (4.6) 
1 (0.7) 
0 (0.0) 
23 (17.3) 
2 (1.5) 
1 (0.7) 
3 (2.3) 
8 (6.0) 
110 (82.7) 
92 (69.2) 
47 (35.3) 
17 (12.8) 
The high percentage of the CTX-M genotype of ESBL-
producing Enterobacteriaceae detected in our study reflects 
the worldwide trend of the spread of these multiresistant 
pathogens to the community.10 Future screening strategies 
may have to take this expanding epidemiology into account. 
Important limitations of our study are its observational 
design, its being conducted at a single center, and the small 
sample size, limiting generalizability. Only hospitalized pa-
tients with detection of ESBLs in any clinical specimen rou-
tinely taken for suspected infection and not receiving anti-
biotics active against ESBL-producing Enterobacteriaceae at 
the time of swabbing were included, so the results cannot 
necessarily be extrapolated to an outpatient setting or to 
healthy individuals. 
We conclude that a standardized screening regimen for 
ESBL-producing Enterobacteriaceae should include both 
urine samples and rectal swabs. 
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